Advanced Bio Healing

Site navigation

Navigation

Press Releases

Advanced BioHealing to Discuss Evolution of a Regenerative Medicine Franchise


La Jolla, Calif. – June 23, 2010 – Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Vice President and General Manager Kathy McGee will be the featured presenter at the San Diego Biotechnology Network event to be held June 23, 2010 from 5:30 to 9:00 p.m. PST at Tango Del Rey in San Diego, Calif.

Ms. McGee will share the story of ABH’s evolution into a multi-million dollar, fully integrated regenerative medicine company. She will discuss ABH’s focus on being the leader in commercializing cell-based technologies, and how that discipline has enabled the production and commercial components of ABH’s business to contribute to the Company’s successes in delivering Dermagraft® to thousands of patients across the country each year.

ABH will also have a booth at the event and representatives will be present to network with attendees throughout the evening.

The San Diego Biotechnology Network was founded in September of 2008 to address the need for more high quality, face to face networking among Biotech professionals in the greater San Diego area.

For more information on the event, please visit http://sdbn.org/2010/05/31/june-sdbn-event/.

About Advanced BioHealing, Inc.
Advanced BioHealing develops and commercializes living cell therapies that repair damaged human tissue and enable the body to heal itself. A privately held company, Advanced BioHealing maintains its corporate office in Westport, Conn. and has two other sites in La Jolla, Calif. and Nashville, Tenn. To meet Advanced BioHealing’s executives and learn more about the Company, please visit the Company’s web site at www.ABH.com.

About Dermagraft®
Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process. It is FDA approved to treat diabetic foot ulcers and is the focus of an ongoing pivotal trial in subjects with venous leg ulcers (VLUs) to assess the product’s safety and efficacy in the promotion of healing VLUs. To date, more than 200,000 applications of Dermagraft have been administered in over 1,000 wound care centers and outpatient clinics nationwide. For videos of Dermagraft in action, case studies, research and more, visit www.Dermagraft.com.

Media Contacts:

  • Lindsey Hart
    • Advanced BioHealing
    • lhart@abh.com
    • Direct: (773) 697-3838
    • Cell: (206) 335-0114
  • Mike Lizun